中国妇幼健康研究
中國婦幼健康研究
중국부유건강연구
Chinese Journal of Woman and Child Health Research
2015年
4期
754-756,768
,共4页
二甲双胍%胰岛素%妊娠期糖尿病%分娩结局
二甲雙胍%胰島素%妊娠期糖尿病%分娩結跼
이갑쌍고%이도소%임신기당뇨병%분면결국
metformin%insulin%gestational diabetes%delivery outcomes
目的 探讨在妊娠期糖尿病中二甲双胍药物治疗的应用价值. 方法 按随机数字表法,将150例妊娠期糖尿病患者分为二甲双胍组(患者确诊后接受单纯二甲双胍治疗)及胰岛素组(患者确诊后接受诺和锐特充胰岛素治疗) ,每组75例;二甲双胍组在接受治疗后血糖控制仍未达标者给予联合应用胰岛素治疗,为联合组,31例. 对比3组接受治疗后血糖控制水平及妊娠结局. 结果 各组分娩后空腹血糖(FBG)、餐后2h血糖水平(2hPBG)及糖化血红蛋白(HbA1c)比较,差异均无统计学意义(均P>0.05). 各组间分娩孕周、妊娠期高血压发生率及子痫前期发生率比较,差异均无统计学意义(均P>0.05),但二甲双胍组阴道分娩率(34.09%)明显低于胰岛素组(57.33%)及联合组(58.06%)(χ2 值分别为5.996、4.242,均P<0.05),而胰岛素组与联合组阴道分娩率比较,差异无统计学意义(P>0.05). 3组胎儿存活率、黄疸率、短暂呼吸急促(TTN)率及呼吸窘迫综合征(RDS)率比较,差异均无统计学意义(均P>0.05),但二甲双胍组出生体重大于胎龄儿(LGA)率、出生体重小于胎龄儿(SGA)率及低血糖发生率分别为4.55%、6.82%和4.55%,联合组为3.23%、6.45%和6.45%,均明显低于胰岛素组的20.00%、22.67%和21.33%(χ2 =9.121,P=0.010;χ2 =7.672,P=0.022;χ2 =8.365,P=0.015),而二甲双胍组与联合组比较,差异均无统计学意义(均P>0 .05 ). 结论 在患有妊娠糖尿病的产妇中,通过应用二甲双胍药物进行血糖控制治疗,可有效地改善患者的分娩结局.
目的 探討在妊娠期糖尿病中二甲雙胍藥物治療的應用價值. 方法 按隨機數字錶法,將150例妊娠期糖尿病患者分為二甲雙胍組(患者確診後接受單純二甲雙胍治療)及胰島素組(患者確診後接受諾和銳特充胰島素治療) ,每組75例;二甲雙胍組在接受治療後血糖控製仍未達標者給予聯閤應用胰島素治療,為聯閤組,31例. 對比3組接受治療後血糖控製水平及妊娠結跼. 結果 各組分娩後空腹血糖(FBG)、餐後2h血糖水平(2hPBG)及糖化血紅蛋白(HbA1c)比較,差異均無統計學意義(均P>0.05). 各組間分娩孕週、妊娠期高血壓髮生率及子癇前期髮生率比較,差異均無統計學意義(均P>0.05),但二甲雙胍組陰道分娩率(34.09%)明顯低于胰島素組(57.33%)及聯閤組(58.06%)(χ2 值分彆為5.996、4.242,均P<0.05),而胰島素組與聯閤組陰道分娩率比較,差異無統計學意義(P>0.05). 3組胎兒存活率、黃疸率、短暫呼吸急促(TTN)率及呼吸窘迫綜閤徵(RDS)率比較,差異均無統計學意義(均P>0.05),但二甲雙胍組齣生體重大于胎齡兒(LGA)率、齣生體重小于胎齡兒(SGA)率及低血糖髮生率分彆為4.55%、6.82%和4.55%,聯閤組為3.23%、6.45%和6.45%,均明顯低于胰島素組的20.00%、22.67%和21.33%(χ2 =9.121,P=0.010;χ2 =7.672,P=0.022;χ2 =8.365,P=0.015),而二甲雙胍組與聯閤組比較,差異均無統計學意義(均P>0 .05 ). 結論 在患有妊娠糖尿病的產婦中,通過應用二甲雙胍藥物進行血糖控製治療,可有效地改善患者的分娩結跼.
목적 탐토재임신기당뇨병중이갑쌍고약물치료적응용개치. 방법 안수궤수자표법,장150례임신기당뇨병환자분위이갑쌍고조(환자학진후접수단순이갑쌍고치료)급이도소조(환자학진후접수낙화예특충이도소치료) ,매조75례;이갑쌍고조재접수치료후혈당공제잉미체표자급여연합응용이도소치료,위연합조,31례. 대비3조접수치료후혈당공제수평급임신결국. 결과 각조분면후공복혈당(FBG)、찬후2h혈당수평(2hPBG)급당화혈홍단백(HbA1c)비교,차이균무통계학의의(균P>0.05). 각조간분면잉주、임신기고혈압발생솔급자간전기발생솔비교,차이균무통계학의의(균P>0.05),단이갑쌍고조음도분면솔(34.09%)명현저우이도소조(57.33%)급연합조(58.06%)(χ2 치분별위5.996、4.242,균P<0.05),이이도소조여연합조음도분면솔비교,차이무통계학의의(P>0.05). 3조태인존활솔、황달솔、단잠호흡급촉(TTN)솔급호흡군박종합정(RDS)솔비교,차이균무통계학의의(균P>0.05),단이갑쌍고조출생체중대우태령인(LGA)솔、출생체중소우태령인(SGA)솔급저혈당발생솔분별위4.55%、6.82%화4.55%,연합조위3.23%、6.45%화6.45%,균명현저우이도소조적20.00%、22.67%화21.33%(χ2 =9.121,P=0.010;χ2 =7.672,P=0.022;χ2 =8.365,P=0.015),이이갑쌍고조여연합조비교,차이균무통계학의의(균P>0 .05 ). 결론 재환유임신당뇨병적산부중,통과응용이갑쌍고약물진행혈당공제치료,가유효지개선환자적분면결국.
Objective To study the application value of metformin in therapy for gestational diabetes.Methods According to random number table method, 150 cases of gestational diabetes were randomly divided into metformin group ( only metformin therapy after diagnosed) and insulin group ( insulin therapy after diagnosed) with 75 cases in each group.Patients in metformin group not meeting the standard of blood glucose were given insuline together, and they were enrolled in combination group (31 cases).The blood sugar control level and pregnancy outcomes of three groups after treatment were compared.Results The fasting blood glucose (FBG), 2h postprandial blood glucose (2hPBG) and glycosylated hemoglobin (HbA1c) were not statistically different among three groups (all P>0.05).There was no statistical difference in gestational age and the incidence of gestational hypertension and eclampsism among three groups ( all P>0.05).The vaginal birth rate in metformin group (34.09%) was significantly lower than in insulin group (57.33%) and in combination group (58.06%) (χ2 value was 5.996 and 4.242, respectively, both P<0.05), but there was no significant difference between insulin group and combination group (P>0.05).There were no statistical differences in fetal survival rate, rate of jaundice, transient tachypnea (TTN) rate and the rate of respiratory distress syndrome (RDS) among three groups (all P>0.05).The rate of birth weight larger than gestational age ( LGA) , the rate of birth weight smaller than gestational age ( SGA) and the incidence of hypoglycemia in metformin group (4.55%, 6.82%, 4.55%) and combination group (3.23%, 6.45%, 6.45%) were lower than those in insulin group (20.00%, 22.67%, 21.33%) (χ2 =9.121,P=0.010;χ2 =7.672,P=0.022;χ2 =8.365,P=0.015), but there was no statistical difference between metformin group and combination group (P>0.05).Conclusion For patients with gestational diabetes, controlling blood sugar by metformin can effectively improve the birth outcomes.
